Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Syncope Article
This is a selection made from among articles on Drug Treatment Syncope. For a permanent link to this article, or to bookmark it for future reading, click here.
from:
Alcohol Rehab and Dual Diagnosis Treatment Today
By Jonathan Huttner
Alcohol Rehab and Dual Diagnosis Treatment Individuals who struggle with both mental illness and a substance abuse problem face special challenges in alcohol rehab. A quality alcohol rehab program recognizes the unique challenges of dually diagnosed clients and offers dual diagnosis treatment in their alcohol rehab center.
Dual Diagnosis Treatment Philosophy in a Alcohol Rehab Program
In years past, alcohol rehabs actually treated mental illness and substance abuse separately. It would not be uncommon to see a patient enter a alcohol rehab for alcohol rehabilitation and then be transferred to a mental health center for dual diagnosis treatment. Today, the quality alcohol rehabs treat alcoholism and psychiatric disorders concurrently and with much better results.
Key Elements in an Alcohol Rehab Program for Dual Diagnosis Treatment An alcohol rehabilitation program designed to treat dual diagnosis must have a psychiatrist that is trained in addiction medicine. In addition to the psychiatrist the staff in the alcohol treatment center must have a thorough understanding of mental health disorders and how to treat them. While alcohol rehabilitation can move along at a steady pace, dual diagnosis treatment is much more gradual. Most people who are admitted to an alcohol rehab program and are dually diagnosed will generally be able to follow the overall guidelines of the alcohol rehab center.
If it becomes apparent they are too impaired from a mental health perspective, they may require transfer from the alcohol rehab with dual diagnosis treatment services to an actual psychiatric hospital.For additional information relating to an effective dual diagnosis treatment center or quality alcohol rehabs, please go to www.dual-diagnosis-treatment-center.com or call the national alcohol rehabilitation helpline at 1-800-511-9225.
Jonathan Huttner is one of the founders of a national addiction treatment helpline 1-800-511-9225, which can help you locate effective treatment anywhere in the United States.
Article Source: http://EzineArticles.com/?expert=Jonathan_Huttner
http://EzineArticles.com/?Alcohol-Rehab-and-Dual-Diagnosis-Treatment-Today&id=632348
Drug Treatment Syncope Specific links
Drug Treatment Syncope News
Shire to Present Scientific Data Across Range of Psychiatric Disorders at ... - MarketWatch (press release)
Shire to Present Scientific Data Across Range of Psychiatric Disorders at ... MarketWatch (press release) Stimulants, such as amphetamines and methylphenidates, are subject to misuse, abuse, addiction, and criminal diversion. Misuse of amphetamines may cause sudden death and serious cardiovascular adverse events. INTUNIV is indicated for the treatment of ... |
Latuda(R) (lurasidone HCl) Label Updated With Expanded Dosing Range Providing ... - MarketWatch (press release)
Latuda(R) (lurasidone HCl) Label Updated With Expanded Dosing Range Providing ... MarketWatch (press release) MARLBOROUGH, Mass., May 05, 2012 (BUSINESS WIRE) -- Sunovion Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved an expanded dose range for LATUDA in the treatment of adult patients with schizophrenia. Latuda® (lurasidone HCl) Label Updated With Expanded Dosing Range Providing ... |
New Study Shows Patients Can Effectively be Switched to Latuda(R) (lurasidone ... - MarketWatch (press release)
New Study Shows Patients Can Effectively be Switched to Latuda(R) (lurasidone ... MarketWatch (press release) LATUDA received US Food and Drug Administration (FDA) approval for the treatment of schizophrenia on October 28, 2010 and is available in pharmacies across the US and Puerto Rico. LATUDA is an atypical antipsychotic indicated for the treatment of ... |
VIVITROL(R) Data to be Presented at Upcoming American Psychiatric Association ... - MarketWatch (press release)
VIVITROL(R) Data to be Presented at Upcoming American Psychiatric Association ... MarketWatch (press release) VIVITROL (naltrexone for extended-release injectable suspension) 380 mg/vial is the first and only once-monthly, extended-release injectable medication for the treatment of alcohol dependence and opioid dependence. The proprietary Medisorb(R) drug ... ALKERMES PLC : VIVITROL® Data to be Presented at Upcoming American Psychiatric ... |
Two New S1P Receptor Modulators Pass Phase 2 Test in MS - Medscape
Two New S1P Receptor Modulators Pass Phase 2 Test in MS Medscape Infections increased slightly with active treatment, and there was some increase in pulmonary issues, a well-known effect of these drugs, as well as some gastrointestinal side effects. "There was 1 patient who developed a maculopathy, a retinal problem ... |
VIVITROL® Data to be Presented at Upcoming American Psychiatric Association ... - EON: Enhanced Online News (press release)
VIVITROL® Data to be Presented at Upcoming American Psychiatric Association ... EON: Enhanced Online News (press release) The proprietary Medisorb ® drug delivery technology in VIVITROL enables the medication to be gradually released into the body at a controlled rate over a one-month time period. Treatment with VIVITROL should be part of a comprehensive treatment program ... |
Dainippon Sumitomo Pharma Reports that Latuda® (lurasidone HCl) Met Primary ... - PharmiWeb.com (press release)
Dainippon Sumitomo Pharma Reports that Latuda® (lurasidone HCl) Met Primary ... PharmiWeb.com (press release) This Phase 3 development program was designed to evaluate the efficacy and safety of LATUDA for the treatment of bipolar I depression. LATUDA received US Food and Drug Administration (FDA) approval for the treatment of adult patients with schizophrenia ... |
Lantheus Medical Imaging Announces Manufacturing and Supply Agreements with ... - MarketWatch (press release)
Lantheus Medical Imaging Announces Manufacturing and Supply Agreements with ... MarketWatch (press release) Lantheus and Jubilant HollisterStier share a dedication to quality and commitment to providing safe and effective drug products. We look forward to working together to bring these innovative products to market," said Marcelo Morales, Chief Executive ... |
New guidance for young people with Wolff-Parkinson-White (WPW) syndrome - TheHeart.Org
New guidance for young people with Wolff-Parkinson-White (WPW) syndrome TheHeart.Org The guidance is explicitly directed at physicians treating young patients with WPW and defines young people as between eight and 21. At the crux of the document is the question of just when physicians should intervene—and when they shouldn't—in young ... |